Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease
BCR-ABL1–like acute lymphoblastic leukemia (ALL) is a recently identified B-cell ALL (B-ALL)subtype with poor outcome that exhibits a gene expression profile similar to BCR-ABL1-positive ALL but lacks the BCR-ABL1 fusion protein. We examined the outcome of children with BCR-ABL1–like ALL treated wit...
Uložené v:
| Vydané v: | Journal of clinical oncology Ročník 32; číslo 27; s. 3012 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
20.09.2014
|
| Predmet: | |
| ISSN: | 1527-7755, 1527-7755 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | BCR-ABL1–like acute lymphoblastic leukemia (ALL) is a recently identified B-cell ALL (B-ALL)subtype with poor outcome that exhibits a gene expression profile similar to BCR-ABL1-positive ALL but lacks the BCR-ABL1 fusion protein. We examined the outcome of children with BCR-ABL1–like ALL treated with risk-directed therapy based on minimal residual disease (MRD) levels during remission induction.
Among 422 patients with B-ALL enrolled onto the Total Therapy XV study between 2000 and 2007, 344 had adequate samples for gene expression profiling. Next-generation sequencing and/or analysis of genes known to be altered in B-ALL were performed in patients with BCR-ABL1–likeALL who had available material. Outcome was compared between patients with and those without BCR-ABL1–like ALL.
Forty (11.6%) of the 344 patients had BCR-ABL1–like ALL. They were significantly more likely to be male, have Down syndrome, and have higher MRD levels on day 19 and at the end of induction than did other patients with B-ALL. Among 25 patients comprehensively studied for genetic abnormalities, 11 harbored a genomic rearrangement of CRLF2, six had fusion transcripts responsive to ABL tyrosine kinase inhibitors or JAK inhibitors, and seven had mutations involving the Ras signaling pathway. There were no significant differences in event-free survival (90.0% +/- 4.7% [SE] v. 88.4% +/- .9% at 5 years; P = .41or in overall survival (92.5% +/- 4.2% v. 95.1% +/- 1.3% at 5 years; P = .41) between patients with and without BCR-ABL1–like ALL.
Patients who have BCR-ABL1–like ALL with poor initial treatment response can be salvaged with MRD-based risk-directed therapy and may benefit from identification of kinase-activating lesions for targeted therapies. |
|---|---|
| AbstractList | BCR-ABL1–like acute lymphoblastic leukemia (ALL) is a recently identified B-cell ALL (B-ALL)subtype with poor outcome that exhibits a gene expression profile similar to BCR-ABL1-positive ALL but lacks the BCR-ABL1 fusion protein. We examined the outcome of children with BCR-ABL1–like ALL treated with risk-directed therapy based on minimal residual disease (MRD) levels during remission induction.
Among 422 patients with B-ALL enrolled onto the Total Therapy XV study between 2000 and 2007, 344 had adequate samples for gene expression profiling. Next-generation sequencing and/or analysis of genes known to be altered in B-ALL were performed in patients with BCR-ABL1–likeALL who had available material. Outcome was compared between patients with and those without BCR-ABL1–like ALL.
Forty (11.6%) of the 344 patients had BCR-ABL1–like ALL. They were significantly more likely to be male, have Down syndrome, and have higher MRD levels on day 19 and at the end of induction than did other patients with B-ALL. Among 25 patients comprehensively studied for genetic abnormalities, 11 harbored a genomic rearrangement of CRLF2, six had fusion transcripts responsive to ABL tyrosine kinase inhibitors or JAK inhibitors, and seven had mutations involving the Ras signaling pathway. There were no significant differences in event-free survival (90.0% +/- 4.7% [SE] v. 88.4% +/- .9% at 5 years; P = .41or in overall survival (92.5% +/- 4.2% v. 95.1% +/- 1.3% at 5 years; P = .41) between patients with and without BCR-ABL1–like ALL.
Patients who have BCR-ABL1–like ALL with poor initial treatment response can be salvaged with MRD-based risk-directed therapy and may benefit from identification of kinase-activating lesions for targeted therapies. BCR-ABL1–like acute lymphoblastic leukemia (ALL) is a recently identified B-cell ALL (B-ALL)subtype with poor outcome that exhibits a gene expression profile similar to BCR-ABL1-positive ALL but lacks the BCR-ABL1 fusion protein. We examined the outcome of children with BCR-ABL1–like ALL treated with risk-directed therapy based on minimal residual disease (MRD) levels during remission induction.PURPOSEBCR-ABL1–like acute lymphoblastic leukemia (ALL) is a recently identified B-cell ALL (B-ALL)subtype with poor outcome that exhibits a gene expression profile similar to BCR-ABL1-positive ALL but lacks the BCR-ABL1 fusion protein. We examined the outcome of children with BCR-ABL1–like ALL treated with risk-directed therapy based on minimal residual disease (MRD) levels during remission induction.Among 422 patients with B-ALL enrolled onto the Total Therapy XV study between 2000 and 2007, 344 had adequate samples for gene expression profiling. Next-generation sequencing and/or analysis of genes known to be altered in B-ALL were performed in patients with BCR-ABL1–likeALL who had available material. Outcome was compared between patients with and those without BCR-ABL1–like ALL.PATIENTS AND METHODSAmong 422 patients with B-ALL enrolled onto the Total Therapy XV study between 2000 and 2007, 344 had adequate samples for gene expression profiling. Next-generation sequencing and/or analysis of genes known to be altered in B-ALL were performed in patients with BCR-ABL1–likeALL who had available material. Outcome was compared between patients with and those without BCR-ABL1–like ALL.Forty (11.6%) of the 344 patients had BCR-ABL1–like ALL. They were significantly more likely to be male, have Down syndrome, and have higher MRD levels on day 19 and at the end of induction than did other patients with B-ALL. Among 25 patients comprehensively studied for genetic abnormalities, 11 harbored a genomic rearrangement of CRLF2, six had fusion transcripts responsive to ABL tyrosine kinase inhibitors or JAK inhibitors, and seven had mutations involving the Ras signaling pathway. There were no significant differences in event-free survival (90.0% +/- 4.7% [SE] v. 88.4% +/- .9% at 5 years; P = .41or in overall survival (92.5% +/- 4.2% v. 95.1% +/- 1.3% at 5 years; P = .41) between patients with and without BCR-ABL1–like ALL.RESULTSForty (11.6%) of the 344 patients had BCR-ABL1–like ALL. They were significantly more likely to be male, have Down syndrome, and have higher MRD levels on day 19 and at the end of induction than did other patients with B-ALL. Among 25 patients comprehensively studied for genetic abnormalities, 11 harbored a genomic rearrangement of CRLF2, six had fusion transcripts responsive to ABL tyrosine kinase inhibitors or JAK inhibitors, and seven had mutations involving the Ras signaling pathway. There were no significant differences in event-free survival (90.0% +/- 4.7% [SE] v. 88.4% +/- .9% at 5 years; P = .41or in overall survival (92.5% +/- 4.2% v. 95.1% +/- 1.3% at 5 years; P = .41) between patients with and without BCR-ABL1–like ALL.Patients who have BCR-ABL1–like ALL with poor initial treatment response can be salvaged with MRD-based risk-directed therapy and may benefit from identification of kinase-activating lesions for targeted therapies.CONCLUSIONPatients who have BCR-ABL1–like ALL with poor initial treatment response can be salvaged with MRD-based risk-directed therapy and may benefit from identification of kinase-activating lesions for targeted therapies. |
| Author | Roberts, Kathryn G Raimondi, Susana C Jeha, Sima Cheng, Cheng Downing, James R Payne-Turner, Debbie Relling, Mary V Evans, William E Pui, Ching-Hon Li, Yongjin Sandlund, John T Easton, John Pei, Deqing Zhang, Jinghui Coustan-Smith, Elaine Leung, Wing H Becksfort, Jared Campana, Dario Mullighan, Charles G |
| Author_xml | – sequence: 1 givenname: Kathryn G surname: Roberts fullname: Roberts, Kathryn G – sequence: 2 givenname: Deqing surname: Pei fullname: Pei, Deqing – sequence: 3 givenname: Dario surname: Campana fullname: Campana, Dario – sequence: 4 givenname: Debbie surname: Payne-Turner fullname: Payne-Turner, Debbie – sequence: 5 givenname: Yongjin surname: Li fullname: Li, Yongjin – sequence: 6 givenname: Cheng surname: Cheng fullname: Cheng, Cheng – sequence: 7 givenname: John T surname: Sandlund fullname: Sandlund, John T – sequence: 8 givenname: Sima surname: Jeha fullname: Jeha, Sima – sequence: 9 givenname: John surname: Easton fullname: Easton, John – sequence: 10 givenname: Jared surname: Becksfort fullname: Becksfort, Jared – sequence: 11 givenname: Jinghui surname: Zhang fullname: Zhang, Jinghui – sequence: 12 givenname: Elaine surname: Coustan-Smith fullname: Coustan-Smith, Elaine – sequence: 13 givenname: Susana C surname: Raimondi fullname: Raimondi, Susana C – sequence: 14 givenname: Wing H surname: Leung fullname: Leung, Wing H – sequence: 15 givenname: Mary V surname: Relling fullname: Relling, Mary V – sequence: 16 givenname: William E surname: Evans fullname: Evans, William E – sequence: 17 givenname: James R surname: Downing fullname: Downing, James R – sequence: 18 givenname: Charles G surname: Mullighan fullname: Mullighan, Charles G – sequence: 19 givenname: Ching-Hon surname: Pui fullname: Pui, Ching-Hon |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25049327$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkLtOw0AQRVcoiDygp0Jb0tjY-7DjMol4KlIkBHW0j7GyZG2H3TUoHf9Axe_xJTgkSFRz5-rcmdEMUa9uakDoPE3ilCTJ1cNsEZMkZTHnMUsTfoQGKSd5lOec9_7pPhp6_5J05JjyE9QnPGEFJfkAfS3aoJoKPG5KrFbGagc1fjdhhaezx2gynaffH5_WrAEL1QbAdlttVo20wgejsIV2DZURODgQAfQ-6YxfR9o4UDsrrMCJzRZL4buuqXdGF3wD-7u0MrWphMUOvNFtJ7Tx0KGn6LgU1sPZoY7Q88310-wumi9u72eTeaRokYUImFIMoBSszKSUqhxDUmjOSK6UkuOSEp4KSQkUHAotNRBKM62oAF5kRa7ICF3u525c89qCD8vKeAXWihqa1i_TjLKcUEZ5h14c0FZWoJcb113utsu_d5Ifvip98Q |
| CitedBy_id | crossref_primary_10_1016_j_leukres_2015_11_018 crossref_primary_10_1038_s41408_020_0308_3 crossref_primary_10_1016_j_clml_2017_03_299 crossref_primary_10_1002_gcc_22748 crossref_primary_10_1097_MPH_0000000000002419 crossref_primary_10_1200_JCO_2014_59_1636 crossref_primary_10_1200_EDBK_278171 crossref_primary_10_1002_phar_1977 crossref_primary_10_1111_ped_12837 crossref_primary_10_1182_blood_2016_05_707653 crossref_primary_10_1007_s12308_020_00406_8 crossref_primary_10_7759_cureus_90563 crossref_primary_10_1016_j_beha_2021_101242 crossref_primary_10_1097_HS9_0000000000000053 crossref_primary_10_1016_j_leukres_2022_106925 crossref_primary_10_31083_j_fbl2702039 crossref_primary_10_3390_ijms22126411 crossref_primary_10_1016_j_ebiom_2019_09_033 crossref_primary_10_1016_j_neo_2022_100840 crossref_primary_10_1016_j_clml_2017_02_019 crossref_primary_10_1016_j_beha_2017_06_001 crossref_primary_10_3109_10428194_2016_1160085 crossref_primary_10_2147_OTT_S235882 crossref_primary_10_1182_blood_2016_12_758979 crossref_primary_10_1182_blood_2017_06_743252 crossref_primary_10_1080_14737140_2020_1766973 crossref_primary_10_3109_10428194_2016_1160080 crossref_primary_10_3389_fped_2017_00258 crossref_primary_10_1016_j_beha_2023_101511 crossref_primary_10_1182_bloodadvances_2017009845 crossref_primary_10_1007_s12185_017_2371_5 crossref_primary_10_1182_blood_2014_11_551481 crossref_primary_10_1038_s41375_022_01799_4 crossref_primary_10_1111_bjh_15251 crossref_primary_10_1002_cnr2_1587 crossref_primary_10_1038_s41375_021_01419_7 crossref_primary_10_1080_10428194_2021_1933475 crossref_primary_10_1182_blood_2015_09_670166 crossref_primary_10_1182_blood_2015_09_671131 crossref_primary_10_1002_acg2_69 crossref_primary_10_1038_leu_2017_113 crossref_primary_10_1016_j_mayocp_2016_09_010 crossref_primary_10_1080_14728214_2021_1956462 crossref_primary_10_1016_j_beha_2019_101095 crossref_primary_10_1007_s11864_017_0455_3 crossref_primary_10_1002_cam4_3099 crossref_primary_10_1016_j_ejca_2017_06_012 crossref_primary_10_3390_antiox10101616 crossref_primary_10_1016_j_blre_2020_100677 crossref_primary_10_1002_cncr_31669 crossref_primary_10_1016_j_yamp_2021_07_011 crossref_primary_10_1016_j_ejcped_2025_100304 crossref_primary_10_1007_s11912_017_0589_2 crossref_primary_10_1016_j_exphem_2018_07_007 crossref_primary_10_1038_leu_2015_113 crossref_primary_10_1038_ncomms13331 crossref_primary_10_1038_nrclinonc_2015_92 crossref_primary_10_3390_ijms23052755 crossref_primary_10_1182_blood_2016_12_725804 crossref_primary_10_1111_bjh_16207 crossref_primary_10_1177_2040620720927575 crossref_primary_10_12688_f1000research_129490_1 crossref_primary_10_1016_j_beha_2017_07_002 crossref_primary_10_1016_j_tvjl_2015_01_004 crossref_primary_10_1002_cncr_29573 crossref_primary_10_1007_s11899_018_0456_8 crossref_primary_10_1016_j_beha_2017_07_003 crossref_primary_10_1007_s11684_020_0759_8 crossref_primary_10_1002_cncr_29579 crossref_primary_10_1038_s41598_020_78024_8 crossref_primary_10_1002_pbc_25462 crossref_primary_10_1007_s40291_025_00775_9 crossref_primary_10_1182_bloodadvances_2019001008 crossref_primary_10_1007_s12185_022_03501_x crossref_primary_10_1182_blood_2015_01_567842 crossref_primary_10_3389_fcell_2025_1650810 crossref_primary_10_1111_apm_12926 crossref_primary_10_1016_j_blre_2016_09_001 crossref_primary_10_1016_S1470_2045_15_70082_3 crossref_primary_10_1200_JCO_2017_77_3648 crossref_primary_10_1182_blood_2020010144 crossref_primary_10_1016_j_clml_2018_03_014 crossref_primary_10_12688_f1000research_9548_1 crossref_primary_10_7759_cureus_10696 crossref_primary_10_3390_cancers13164068 crossref_primary_10_3390_cancers13174388 crossref_primary_10_1038_nrclinonc_2015_38 crossref_primary_10_1080_10428194_2021_1929964 crossref_primary_10_1182_blood_2018_04_841676 crossref_primary_10_1200_EDBK_280175 crossref_primary_10_1016_j_clml_2020_08_011 crossref_primary_10_1200_JCO_18_00822 crossref_primary_10_1111_bjh_17093 crossref_primary_10_1159_000519782 crossref_primary_10_1097_FPC_0000000000000554 crossref_primary_10_7759_cureus_73988 crossref_primary_10_1136_bcr_2024_259811 crossref_primary_10_1097_MOH_0000000000000315 crossref_primary_10_1111_ped_13457 crossref_primary_10_1016_S2352_4642_18_30066_X crossref_primary_10_21320_2500_2139_2017_10_2_235_249 crossref_primary_10_1038_leu_2015_134 crossref_primary_10_1080_17474086_2021_1967137 crossref_primary_10_1016_j_mjafi_2024_04_017 crossref_primary_10_1080_17474086_2020_1770591 crossref_primary_10_1182_bloodadvances_2018025718 crossref_primary_10_1038_leu_2017_265 crossref_primary_10_3390_ijms26147003 crossref_primary_10_1016_j_blre_2017_09_005 crossref_primary_10_1186_s12885_020_07781_6 crossref_primary_10_1002_gcc_22439 crossref_primary_10_1097_MPH_0000000000001412 crossref_primary_10_3390_genes12050687 crossref_primary_10_1016_j_clml_2024_08_005 crossref_primary_10_1200_EDBK_156628 crossref_primary_10_1186_s12887_024_04991_w crossref_primary_10_24287_1726_1708_2019_18_1_112_126 crossref_primary_10_1016_j_clml_2019_08_003 crossref_primary_10_1200_JCO_2016_70_7836 crossref_primary_10_1016_j_beha_2018_09_003 crossref_primary_10_1016_j_jtct_2024_06_028 crossref_primary_10_1182_blood_2015_03_580027 crossref_primary_10_3389_fonc_2019_01477 crossref_primary_10_1080_17474086_2018_1433030 crossref_primary_10_1007_s11684_015_0381_3 crossref_primary_10_1182_blood_2017_05_783852 crossref_primary_10_1002_cncr_33933 crossref_primary_10_1080_14656566_2017_1340938 crossref_primary_10_1111_bjh_13834 crossref_primary_10_1007_s11899_020_00597_y crossref_primary_10_1182_blood_2015_02_580043 crossref_primary_10_1016_j_pcl_2014_09_004 crossref_primary_10_1007_s11899_016_0337_y crossref_primary_10_1038_s41408_020_0287_4 crossref_primary_10_1111_bjh_17869 crossref_primary_10_1182_blood_2023023153 crossref_primary_10_1002_cncr_29383 crossref_primary_10_1053_j_seminhematol_2018_05_001 crossref_primary_10_1089_jayao_2015_0014 crossref_primary_10_1016_j_blre_2024_101208 crossref_primary_10_3389_fped_2017_00263 crossref_primary_10_1038_leu_2016_234 crossref_primary_10_1186_s13045_015_0145_1 crossref_primary_10_1182_blood_2017_03_735639 crossref_primary_10_1002_pbc_29990 crossref_primary_10_3390_ijms21062193 crossref_primary_10_1182_bloodadvances_2021005576 crossref_primary_10_1111_bjh_14916 crossref_primary_10_1038_s41598_021_85213_6 crossref_primary_10_1016_j_semcancer_2020_10_013 crossref_primary_10_1038_s41571_018_0136_6 crossref_primary_10_1038_bcj_2016_28 crossref_primary_10_3390_jcm10091926 crossref_primary_10_1093_jnci_djaa138 crossref_primary_10_1182_blood_2016_07_726588 crossref_primary_10_1182_blood_2014_11_612903 crossref_primary_10_1200_JCO_2017_74_0449 crossref_primary_10_1111_bjh_13896 crossref_primary_10_12688_f1000research_16074_1 crossref_primary_10_1093_labmed_lmz008 crossref_primary_10_1002_cncr_31848 crossref_primary_10_1016_j_beha_2021_101331 crossref_primary_10_1007_s00277_023_05241_2 crossref_primary_10_1002_cncr_34606 crossref_primary_10_1182_blood_2024026381 crossref_primary_10_1016_j_critrevonc_2018_04_002 crossref_primary_10_1007_s12288_018_0997_y crossref_primary_10_1080_14737159_2017_1377073 crossref_primary_10_1172_JCI134424 crossref_primary_10_3389_fonc_2024_1498409 crossref_primary_10_1016_j_bbmt_2019_08_014 crossref_primary_10_3889_oamjms_2022_9139 crossref_primary_10_3389_fphar_2021_749361 crossref_primary_10_1016_j_bbmt_2019_08_010 crossref_primary_10_1186_s12920_024_01892_w |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2014.55.4105 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 25049327 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA36401 – fundername: NCI NIH HHS grantid: R01 CA036401 – fundername: NIGMS NIH HHS grantid: GM92666 – fundername: NIGMS NIH HHS grantid: U01 GM092666 – fundername: NCI NIH HHS grantid: R37 CA036401 – fundername: NCI NIH HHS grantid: P30 CA021765 – fundername: NCI NIH HHS grantid: CA21765 |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AARDX AAWTL AAYEP AAYOK ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VVN WH7 X7M YCJ YFH YQY 7X8 ABBLC |
| ID | FETCH-LOGICAL-c396t-e4cc4eefa4f6bbbcf8e09d5427cccb8f3251ab32e95e9dbde2336dc3ae59697c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 190 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000342062200015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Fri Sep 05 11:14:44 EDT 2025 Thu Apr 03 07:10:56 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 27 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c396t-e4cc4eefa4f6bbbcf8e09d5427cccb8f3251ab32e95e9dbde2336dc3ae59697c2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2014.55.4105?role=tab |
| PMID | 25049327 |
| PQID | 1634723435 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1634723435 pubmed_primary_25049327 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-09-20 |
| PublicationDateYYYYMMDD | 2014-09-20 |
| PublicationDate_xml | – month: 09 year: 2014 text: 2014-09-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2014 |
| References | 23334668 - Nat Genet. 2013 Mar;45(3):242-52 22237106 - Nature. 2012 Jan 12;481(7380):157-63 22955920 - Blood. 2012 Oct 25;120(17):3510-8 17344859 - Nature. 2007 Apr 12;446(7137):758-64 21863287 - Int J Hematol. 2011 Sep;94(3):255-60 19641190 - Blood. 2009 Sep 24;114(13):2688-98 19805687 - J Clin Oncol. 2009 Nov 1;27(31):5175-81 19838194 - Nat Genet. 2009 Nov;41(11):1243-6 21680795 - Blood. 2011 Sep 15;118(11):3080-7 9718381 - N Engl J Med. 1998 Aug 27;339(9):605-15 22368272 - Blood. 2012 Apr 12;119(15):3512-22 17234643 - Bioinformatics. 2007 Mar 15;23(6):657-63 22897847 - Cancer Cell. 2012 Aug 14;22(2):153-66 22436535 - Blood Rev. 2012 May;26(3):123-35 19129520 - N Engl J Med. 2009 Jan 29;360(5):470-80 12011421 - Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 24186319 - Haematologica. 2013 Nov;98(11):e146-8 23212523 - Blood. 2013 Jan 17;121(3):485-8 11023499 - Blood. 2000 Oct 15;96(8):2691-6 20699438 - Blood. 2010 Dec 2;116(23):4874-84 23953334 - Semin Hematol. 2013 Jul;50(3):185-96 22898679 - Lancet Oncol. 2012 Sep;13(9):936-45 22685175 - Blood. 2012 Jul 26;120(4):833-42 19138562 - Lancet Oncol. 2009 Feb;10(2):125-34 19553647 - N Engl J Med. 2009 Jun 25;360(26):2730-41 24013638 - Nat Genet. 2013 Oct;45(10):1226-31 19470474 - Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 23835704 - J Clin Oncol. 2013 Sep 1;31(25):e413-6 24141364 - Nat Genet. 2013 Dec;45(12):1494-8 23974192 - Blood. 2013 Oct 10;122(15):2622-9 15029212 - Leukemia. 2004 May;18(5):934-8 20139093 - Blood. 2010 Jul 1;115(26):5312-21 19052058 - Bioinformatics. 2009 Feb 1;25(3):315-21 |
| References_xml | – reference: 9718381 - N Engl J Med. 1998 Aug 27;339(9):605-15 – reference: 22897847 - Cancer Cell. 2012 Aug 14;22(2):153-66 – reference: 24186319 - Haematologica. 2013 Nov;98(11):e146-8 – reference: 19641190 - Blood. 2009 Sep 24;114(13):2688-98 – reference: 11023499 - Blood. 2000 Oct 15;96(8):2691-6 – reference: 20139093 - Blood. 2010 Jul 1;115(26):5312-21 – reference: 19129520 - N Engl J Med. 2009 Jan 29;360(5):470-80 – reference: 22685175 - Blood. 2012 Jul 26;120(4):833-42 – reference: 15029212 - Leukemia. 2004 May;18(5):934-8 – reference: 19553647 - N Engl J Med. 2009 Jun 25;360(26):2730-41 – reference: 17234643 - Bioinformatics. 2007 Mar 15;23(6):657-63 – reference: 17344859 - Nature. 2007 Apr 12;446(7137):758-64 – reference: 19470474 - Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 – reference: 19838194 - Nat Genet. 2009 Nov;41(11):1243-6 – reference: 22955920 - Blood. 2012 Oct 25;120(17):3510-8 – reference: 23334668 - Nat Genet. 2013 Mar;45(3):242-52 – reference: 23953334 - Semin Hematol. 2013 Jul;50(3):185-96 – reference: 23835704 - J Clin Oncol. 2013 Sep 1;31(25):e413-6 – reference: 20699438 - Blood. 2010 Dec 2;116(23):4874-84 – reference: 19805687 - J Clin Oncol. 2009 Nov 1;27(31):5175-81 – reference: 21680795 - Blood. 2011 Sep 15;118(11):3080-7 – reference: 22436535 - Blood Rev. 2012 May;26(3):123-35 – reference: 24141364 - Nat Genet. 2013 Dec;45(12):1494-8 – reference: 24013638 - Nat Genet. 2013 Oct;45(10):1226-31 – reference: 22237106 - Nature. 2012 Jan 12;481(7380):157-63 – reference: 12011421 - Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 – reference: 19138562 - Lancet Oncol. 2009 Feb;10(2):125-34 – reference: 22368272 - Blood. 2012 Apr 12;119(15):3512-22 – reference: 23974192 - Blood. 2013 Oct 10;122(15):2622-9 – reference: 19052058 - Bioinformatics. 2009 Feb 1;25(3):315-21 – reference: 22898679 - Lancet Oncol. 2012 Sep;13(9):936-45 – reference: 23212523 - Blood. 2013 Jan 17;121(3):485-8 – reference: 21863287 - Int J Hematol. 2011 Sep;94(3):255-60 |
| SSID | ssj0014835 |
| Score | 2.5615091 |
| Snippet | BCR-ABL1–like acute lymphoblastic leukemia (ALL) is a recently identified B-cell ALL (B-ALL)subtype with poor outcome that exhibits a gene expression profile... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 3012 |
| SubjectTerms | Adolescent Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Child Child, Preschool Disease-Free Survival Female Fusion Proteins, bcr-abl - drug effects Fusion Proteins, bcr-abl - genetics Gene Expression Profiling Humans Infant Kaplan-Meier Estimate Male Molecular Targeted Therapy - methods Neoplasm, Residual - drug therapy Neoplasm, Residual - genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Risk Assessment Risk Factors Salvage Therapy - methods |
| Title | Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/25049327 https://www.proquest.com/docview/1634723435 |
| Volume | 32 |
| WOSCitedRecordID | wos000342062200015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSxxBEG4SDcGLJuah0YQOBE-27k53z-MkukRCiOsSDOxtma6uhsV1Rp1dYW_-B0_-vfwSq2Zm2ZMQyGUODd09Q9VUfdRXDyG-8SQa8I45wzhTxger0tx1FcQkbx2HbieEethE0u-nw2E2aANuVZtWubCJtaH2JXCM_JBwg0kiTd796PpG8dQoZlfbERovxaomKMNanQyXLIJJ6wGbPLmVUKS1LU1JinH4s3fOeV3mwNoDznR8HmDWjuZ0439f8Y1YbyGmPG504q14gcWmeH3WkuibYm_QtKue78uLZfVVtS_35GDZyHr-Tjyez6Z0M1ayDHJR9S05citPer_V8cmv7t_7h8n4EmUOsynKyZx0o3QEyOlAOcHZJV6Nc1kns6NvdnIuu2ocKS015V9zyc7Uy7LgBdp4Rx6bL-XGJ1f0LbdY1UVjsuWT3os_p98vej9UO8pBgc7iqUIDYBBDbkLsnIOQYifz1kQJALg0aIJZudMRZhYz7zxGWscedI42i7MEog9ipSgL3BJSW3QxYKrJNBoT6Mhubgn0WIKGtgOwLb4upDOiX4X5j7zAclaNlvLZFh8bEY-um54eI-7kRlA2-fQPu3fEGqsOZ41EnV2xGshQ4GfxCu6m4-r2S62D9OwPzp4AEWvqiA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Outcomes+of+children+with+BCR-ABL1%E2%80%93like+acute+lymphoblastic+leukemia+treated+with+risk-directed+therapy+based+on+the+levels+of+minimal+residual+disease&rft.jtitle=Journal+of+clinical+oncology&rft.au=Roberts%2C+Kathryn+G&rft.au=Pei%2C+Deqing&rft.au=Campana%2C+Dario&rft.au=Payne-Turner%2C+Debbie&rft.date=2014-09-20&rft.eissn=1527-7755&rft.volume=32&rft.issue=27&rft.spage=3012&rft_id=info:doi/10.1200%2FJCO.2014.55.4105&rft_id=info%3Apmid%2F25049327&rft_id=info%3Apmid%2F25049327&rft.externalDocID=25049327 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |